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Abstract 
Water quality is fundamental to haemodialysis regardless of the modality; this has 
two distinct strands namely chemical quality and microbiological quality.  However, 
the water quality is far more critical with the high volume online haemodiafiltration 
(HiVOLHDF)* modality of treatment.  A typical adult will be exposed to approximately 
fourteen litres of water a week. This is ingested orally, absorbed via the 
gastrointestinal tract, any excess is removed by the nephron in the kidney and exits 
the body with other waste products of metabolism in the urine.  By contrast, the 
standard thrice weekly haemodialysis patient is exposed to 576 litres per week via 
the semipermeable dialyser. In addition, the high volume online HDF patient is 
exposed typically to an additional 60 L per week which is infused directly into the 
patient’s blood stream.  Furthermore, as the majority of End Stage Renal Disease 
(ESRD) patients have zero, or very minimal residual renal function, toxins in the 
blood remain and cannot be ‘renally’ excreted between dialysis sessions. 
From the literature review, it has been unequivocally demonstrated that water quality 
is an essential component to the dialysis process. However, as of 2016 there is not a 
scientific consensus with regard to whether HiVOLHDF is a superior treatment of 
ESRD patients with regard to mortality and morbidity.  Whilst this may be the current 
case, it is the author’s belief that this will be forthcoming in due course.  In the 
interim, it should be considered best practice to strive towards implementation of 
ultrapure water systems in all dialysis units and performing HiVOLHDF, while we 
await the evidence.  This viewpoint is compounded by the fact that there have been 
no negative reports from the studies reviewed relating to patient outcomes when 
treatment by HiVOLHDF versus alternative conventional haemodialysis treatments. 
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In addition, it would definitely seem prudent that when designing new dialysis 
facilities, ultrapure water should be considered the standard specification. 
This organisational development involved the transfer of an existing haemodialysis 
unit to a new state-of-the art redeveloped facility within the organisation. This facility 
would offer ultrapure water to facilitate HiVOLHDF as standard. There were 
numerous change strands to this project and the author incorporated the HSE 
change model and the CIPP evaluation framework to evaluate and guide the 
process.   
*The acronym HiVOLHDF has been developed by the author for the purpose of this 
project. 
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1. Introduction 
  
Kidney failure or disease is predominately defined as a reduction in the glomerular 
filtration rate within the nephron which leads to inefficient waste product removal 
(e.g. creatinine, urea) and a reduction or cessation of urine production.  This is 
categorised as being either acute or chronic kidney disease (AKD) or (CKD). There 
are numerous causes of kidney failure the most common being; diabetes, 
hypertension, glomerulonephritis and polycystic kidney disease.  As seen in figure 1, 
the two predominant causes of CKD from the United States are diabetes and 
hypertension. 
 
Figure 1 
(Levey et al., 2003) 
There is no cure for CKD but numerous treatment options exist, from an array of 
dialysis modalities to transplantation. Writing in the Lancet, Levey and Coresh warn 
of the significant worldwide health threat stemming from the increased prevalence of 
CKD and the ever increasing costs associated with both dialysis and transplantation.  
This coupled with the emerging obesity epidemic and the ageing population provides 
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significant healthcare challenges to both the developing and developed worlds. 
(Levey & Coresh, 2012). 
 
In the 2010 Global Burden of Disease report, CKD was ranked 18th as the cause of 
death compared with 27th in 1990.  This rate of increase was second only to HIV and 
AIDS. In England, the NHS Kidney Care reports that the costs associated with the 
treatment of CKD exceeds the combined total spent on breast, lung, colon  and skin 
cancer treatments. While in the US, the total annual cost of treatment of CKD 
patients is circa $48(US) billion and accounts for 6.7% of the total Medicare budget 
treating less than 1% of the covered population. In Australia, the predicted cost to 
treat current and future CKD patients through to 2020 is $12(AUS) billion. (Jha et al., 
2013).   In Ireland while 0.03 per cent of the population require dialysis, 2-3 per cent 
of the overall healthcare budget is consumed by it. (Culliton, 2009). 
 
There are a variety of renal replacement therapies (RRT) available for the treatment 
of patients with acute or chronic end-stage renal disease (ESRD).  These include, 
but are not limited to, continuous ambulatory peritoneal dialysis (CAPD), low and 
high flux haemodialysis (HD), home haemodialysis (HHD) nocturnal dialysis, 
haemofiltration (HF), online haemodiafiltration (OLHDF) and increasingly, high 
volume OLHDF (HiVOLHDF).  For the purpose of this document and project the 
author has developed the acronym HiVOLHDF. 
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The focal point of this organisational development is the relocation of inpatient acute 
haemodialysis services, at a large acute teaching hospital, to a refurbished ultra-
modern facility.  This new unit will be equipped with state-of-the-art technologies 
from the water purification plant to the haemodialysis machines and this will facilitate 
(HiVOLHDF), which may be the best dialysis treatment to date, in terms of mortality 
and morbidity.  As discovered in this document, fundamental to all dialysis 
treatments is water quality, and with the evolution of therapies from low-flux to 
HiVOLHDF, stringent purity requirements have become crucial. Additionally, this will 
enable the treatment of our acute haemodialysis population in a fit-for-purpose 
environment with increased capacity.   
 
 
1.1 Rationale 
1.1.1 Current Facilities and proposed relocation 
 
There are two units in this organisation providing dialysis treatments. Acute renal 
inpatients (and some chronic haemodialysis patients) are treated in the 8-bedded 
acute unit in St. Peter’s ward on the 4th Floor. This unit was commissioned in March 
1999. The configuration of the ward (4, 2, 2) does not allow for patient isolation 
requirements.  In addition, the unit is now in its sixteenth year and is no longer fit for 
purpose.  The treatment modality performed in this unit was low flux HD owing to 
limitations of the ageing water purification equipment; this will be addressed in more 
detail in chapter four.  Regarding the latest standards for space between dialysis 
stations, infection control, fire and safety and patient dignity requirements, updating 
is required.  This acute unit will be re-located to another section of St Peters Ward.  
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The CAPD and the Pre-Dialysis Programme, currently in St Peter’s ward will be 
therefore relocated to St Monica’s Ward to facilitate this move. 
 
A new central delivery and water supply system needs to be installed in the acute in-
patient haemodialysis unit.  The proposed move to a new expanded location on St. 
Peter’s Ward (with a 4,4,1 configuration) would also offer an area that meets 
European standards relating to treatment of isolated patients.  It would solve space 
and infection control issues, and improve overall patient care, while fulfilling the 
Health Information and Quality Authority (HIQA) and Joint Commission International 
(JCI) recommendations.  The new location will provide improved conditions for all 
and eliminate the overcrowding of corridors with dialysis and related equipment as 
identified by fire safety officers and JCI. 
 
The second unit is a 9-station chronic haemodialysis unit and is based on the ground 
floor of the clinical services building and will remain there.  This unit operates with 
ultrapure water and performs HiVOLHDF.   
1.1.2 Reverse Osmosis (RO) and Pre-treatment 
  
The existing Reverse Osmosis (RO) and Pre-treatment system requires significant 
on-going maintenance including the replacement of costly RO and Ultrasafe 
membranes.  The proposed relocation of the acute dialysis unit will standardise the 
RO systems across the hospital and will provide a double-pass reverse-osmosis unit 
replacing the present single RO/Ultrasafe system. 
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As the acute dialysis unit provides a six day dialysis service (on call provided on 
Sundays) which requires constant surveillance and maintenance, the new pre-
treatment plant work load will be reduced, as the 4th floor system will be a duty 
standby system.  The new system will be more environmentally friendly and provide 
heat sanitisation instead of routinely using chemicals. 
 
1.1.3 Central Delivery System 
 
The existing acute dialysis unit does not have a central delivery system for 
concentrates.  Under the proposed relocation, a new central delivery system 
mirroring the system in place on the chronic haemodialysis unit on the ground floor 
will be introduced.  A centralised delivery system will reduce concentrate waste and 
storage requirements.  In addition, it provides for better manual handling conditions 
as staff no longer need to carry six kilogram fluid containers. 
 
1.2 Aim and Objectives 
 
1.2.1 Aim 
 
The aim of this organisational development is to relocate and expand the existing 
acute inpatient haemodialysis service to a new, refurbished and fit-for-purpose 
location, with a dedicated isolation facility and increased capacity.  The new facility 
will provide ultrapure water to facilitate HiVOLHDF as the treatment modality of 
choice. 
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1.2.2 Objectives 
 
This operational development (OD) will incorporate the following SMART objectives 
(Specific, Measurable, Attainable, Realistic, Timely). 
 
1. By June 3rd 2015, complete and submit a business case to the National 
Renal Office and the Ireland East Hospitals Group (IEHG) for approval of funding.  
2. By August 21st 2015, have the contractors’ schematics for the new unit 
agreed by all stakeholders. 
3. From 5th October 2015, commence installation of water purification plant, 
centralised concentrate delivery system (CCDS) and associated ring mains. 
4. By 7th December 2015, commence quality testing and commissioning of 
water purification plant and CCDS. This intensive sampling phase will be completed 
by January 4th 2016 and will incorporate the development of a Key Performance 
Indicator (KPI). 
5. On 8th February 2016, transfer acute haemodialysis services to the new unit 
and cease services at the current unit. 
6. By February 2016, establish a dedicated isolation unit and increase treatment 
capacity by 12.5%  
7. By February 2016, address fire officer and JCI non compliances 
8. By April 2016, perform and evaluate patient and staff satisfaction surveys to 
ascertain both cohorts’ experience of the new facilities. 
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1.3 Organisational context 
 
The Department of Nephrology at this organisation currently has a 9-station chronic 
haemodialysis unit, an 8-station acute in-patient haemodialysis unit, a CAPD 
programme and a Pre-Dialysis programme. As well as offering services in 
nephrology and hypertension, the department is a major contributor to the 
organisation’s Emergency Services.  
 
The department also provides a kidney transplant management service in 
conjunction with Beaumont Hospital (National Renal Transplant centre). There has 
been an increase of more than 50% in the number of patients receiving post-
transplant multidisciplinary care (120 patients in August 2015).   New links between 
this organisation and a large London transplant hospital have resulted in a paired-
kidney exchange program in the UK.  This has also caused transplant patient 
numbers to rise by offering alternative routes to kidney transplantation. 
 
The numbers of end-stage renal patients managed by this organisation has 
expanded considerably in the last decade. This growth has largely been 
accommodated by the establishment of a satellite dialysis unit.  
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Haemodialysis Treatments: 
 
 OPD/Chronic 
HD Patients 
 
Satellite 
Chronic 
Patients under 
Organisations 
Governance 
Acute Patients Total HD 
Patients 
Treatments  
2009 79                40 72 12,321 
2010 79 36 96 12,868 
2011 80 39 84 13,173 
2012 80 41 98 12,386 
2013 82 43 162 13,087 
2014 80 47 110 12,082 
 
Figure 2. Organisational haemodialysis statistics from 2015 
 
The dialysis treatment of choice for all is HiVOLHDF, a treatment that combines the 
benefits of conventional haemodialysis, haemofiltration and haemodiafiltration in one 
therapy and potentially mirrors the function of the natural Kidney.  HiVOLHDF has 
proven beneficial clinical outcomes for long-term haemodialysis patients with a 
reduced incidence of cardiovascular and rheumatological complications. (Ward, 
Schmidt, Hullin, Hillebrand, & Samtleben, 2000).  It is the intention of the Department 
of Nephrology to introduce this therapy as its treatment of choice on a phased basis.  
A significant emphasis on water quality is required as the HiVOLHDF process 
involves infusing large volumes of ultrapure water directly into the patient’s 
bloodstream. (J. E. Tattersall & Ward, 2013). 
 
The nephrology department has an active research programme and participates in 
the Newman Scholarship Programme with the Conway Institute in University College 
Dublin. 
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1.4 Role of the student in the organisation and the project 
 
The role of the change agent, the author, is to facilitate and lead-out with this service 
development.  As the author is the head of the clinical engineering department and 
thereby responsible for the management of medical technologies and their safe 
deployment for the diagnosis and treatment of patients, this organisational 
development project provides the platform to exhibit and demonstrate the knowledge 
and skills gained from participating in the RCSI MSc in Leadership programme.  It is 
sufficiently challenging so as to highlight how the clinical engineer can successfully 
enact and lead a significant technological organisational development.  
 
The author will use the Health Services Executive (HSE) change model (2009) 
organisational change model for this development. 
 
“It is, therefore, recommended that change initiatives and restructuring processes 
should involve careful assessment and evaluation of the health care environment so 
as to identify critical problem areas such that goals can be effectively set and 
communicated to all stakeholders and strategies can be designed and aligned to 
minimize, if not eradicate, these problem areas.” (Volonté, 2013). 
 
In order to execute the implementation plan for all components of this project, the 
author will perform a literature review and use evaluation tools to evaluate its 
success.  In addition, internal and external stakeholders will be consulted to gain 
approval for the business case and to successfully deliver on the stated aim and 
objectives within the proposed timeframes.   
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1.5 Summary and Conclusion 
 
 
In summary, this project involves the relocation of existing in-patient acute 
haemodialysis services to a new fit for purpose dedicated facility.  Ultimately, and 
most importantly, this will facilitate the optimum care environment for patients and 
ensure the treatment is of the highest quality.  In addition, it will expand the service 
and enable a better facility for clinical staff to operate from.  From a clinical 
engineering perspective, this project has numerous challenges which require a 
special set of skills, namely vision, leadership, negotiation, patience, technical 
capability, self and team trust in addition to project management skills. 
 
In the following chapter, the author will detail the literature review relating to various 
aspects of the treatment modalities and water quality requirements.  The subsequent 
chapters will outline and discuss the change methodology deployed, the evaluations 
performed and the techniques utilised and finally, complete with a discussion and 
conclusion.   
 
 
 
2. Literature Review 
  
2.1 Introduction 
 
As mentioned in chapter 1 there are a variety of renal replacement therapies 
available for the treatment of patients with acute or chronic end-stage renal disease. 
This chapter will outline the search strategy employed, detail the scope of the 
literature review, introduce the HD, HF and OLHDF modalities, discuss the emerging 
themes, review in detail the history and the potential clinical benefits (if proven) of 
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HiVOLHDF and consider the implications for this service development project. 
Finally, the author will summarise this chapter and highlight any significant 
conclusions.  
 
 
2.2 Search strategy 
 
The search methodology consisted of the following search combinations and 
variations of the same: Haemodialysis vs Online HDF, Haemofiltration vs 
Haemodialysis, mortality, morbidity and solute removal, water quality haemodialysis 
and OLHDF.  During the search process, ‘Haemo’ was alternated with ‘Hemo’ to 
reflect international spelling variations. 
In total, forty three articles were selected and sourced using Google Scholar, 
Emerald, PubMed, Medline and Science Direct.  The articles were published 
predominately in; the Journal of the American Society of Nephrology (JASN), 
Nephrology Dialysis and Transplantation (NDT), American Journal of Kidney 
Disease (AJKD), European Journal of Medical Research (EJMR), Kidney 
International, the Journal of the International Society of Nephrology (ISN), The 
Lancet, the British Medical Journal (BMJ), the New England Journal of Medicine 
(NEMJ), the Blood Purification Journal and the European Dialysis & Transplant 
Nurses Association/European Renal Care Association Journal (EDTNA/ERCA).  
After an initial analysis, ten articles were withdrawn as they had been superseded by 
later research and publications, leaving thirty three for this review. The date profile of 
the articles is from 2000 to the present day. 
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2.3 Scope of Literature Review 
 
During this review, the author will research the differences between the selected 
modalities and discover any relative strengths and weaknesses in the treatment of 
patients with ESRD.  In addition, the author will attempt to draw on all expert opinion 
to determine if there is consensus regarding the merits of any dialysis treatment 
versus another.   
 
2.4 Theme 1 Haemodialysis 
 
Haemodialysis is a clinical process by which urea, excessive water and other waste 
products of metabolism are removed from the blood by diffusion. Diffusion, a passive 
process, is defined as the movement of particles from an area of high concentration 
to an area of low concentration. 
 
Haemodialysis is used to treat patients with either chronic, or acute ESRD and other 
blood toxicity conditions. Generally, the patients’ blood is accessed via an 
arteriovenous (AV) fistula and passed through a semi-permeable membrane, the 
dialyser, where the diffusion of solutes and removal of water by ultrafiltration takes 
place and is then returned to the patient's circulation via the AV fistula.  On one side 
of the semi-permeable membrane is the patient’s blood, and on the other is the 
dialysis fluid which is a combination of purified water and a mixture of acidic 
chemicals and bicarbonate buffer.  These fluids are proportionated by the dialysis 
machine into an isotonic biocompatible solution of the correct concentration to 
enable diffusion of predominately small to medium solutes from the patient’s blood.  
The combination of waste solutes and water is referred to as dialysate and is 
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dispensed to soil drain by the haemodialysis machine.  The pore size of the dialyser 
dictates the molecular clearance rate for the treatment and this is referred to as the 
‘flux’ of the dialyser.  With the advancement of water purification technologies 
facilitating the production of high quality dialysis fluid, most centres routinely use 
high-flux dialysers in their haemodialysis treatments, thereby enabling better 
clearance of the low to medium sized solutes.  Low molecular weight solutes are 
typically less than 5 kilodaltons (kDa) whilst the middle molecular weight solutes are 
typically of the order 5–50 kDa.  Later in this chapter the significance of Beta2-
microglobulin (ß2M), which has a molecular weight of 11.8 kDa (van der Weerd et 
al., 2007), will be highlighted.  
 
Conventional haemodialysis uses diffusive forces in the process for the removal of 
toxins from the patient’s blood stream and secondly, excess fluids are removed 
using ultrafiltration.  Historically, haemodialysis was performed thrice weekly with a 
typical fixed duration of four hours.  Currently, for hospitals performing 
haemodialysis, it is common practice for the treatment time to be very patient- 
specific, based on many parameters e.g. the individual patient’s blood chemistry, 
weight gain and their tolerance of ultrafiltration.   Many technological advances, in 
particular single and   blood volume monitoring have facilitated this.  
 
2.5 Theme 2 Haemofiltration 
 
Haemofiltration is primarily used in the intensive care setting for the treatment of 
patients with acute renal impairment, sepsis and multiple organ deterioration.  As 
with haemodialysis, during hemofiltration the patient’s blood is cleansed by the 
movement of solutes across a semi-permeable membrane.  With haemofiltration, 
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however, convection rather than diffusion is the process by which the solutes are 
removed.  ‘Convection is bulk-flow of solute across a semi-permeable membrane 
together with a solvent in a manner that is dependent on transmembrane pressure 
and membrane characteristics.’ (Ronco, Kellum, & Mehta, 2001).  Haemofiltration is 
an active process whereby a positive hydrostatic pressure is applied which drives the 
solutes across the dialyser, enabling a very efficient clearance of molecules of a 
small and medium molecular weight.  The defining factor for the clearance is the 
porosity of the dialyser membrane.  
 
Haemofiltration is more efficient than conventional haemodialysis at removing 
medium solutes owing to the slower diffusion speed in haemodialysis. As 
haemofiltration relies on the plasma concentration of the solutes rather than the 
concentration gradient, as is the case with diffusion, this facilitates the efficient 
removal of medium to low molecular weight solutes.  
 
With haemofiltration, the conventional dialysis fluid is not prepared by the machine 
as is the case with conventional haemodialysis; rather the fluids are commercially 
produced and pumped into the dialyser for the convection process and collected post 
treatment for disposal.  This adds a significant cost to this treatment and, in addition, 
whilst haemofiltration is efficient at removing solutes of middle molecular weight, 
when compared to conventional haemodialysis, it does not achieve the same level of 
low molecular solute clearance as haemodialysis. (Oates, Cross, & Davenport, 2012) 
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2.6 Theme 3 Online Haemodiafiltration 
 
Online Haemodiafiltration (OLHDF) is a technique associated with high ultrafiltration 
rates and diffusion across a highly permeable membrane.  Blood and dialysate are 
circulated as in haemodialysis, but in addition, ultrafiltration, in excess of the 
scheduled weight loss, is provided.  Replacement/substitution fluid is used to 
achieve fluid balance. (Ronco et al., 2001).  This renal replacement therapy 
combines haemodialysis and haemofiltration to achieve the aforementioned benefits 
of both modalities, namely diffusion and convection.  OLHDF involves reinfusion of 
the replacement fluid which is produced by the machine directly into the patient’s 
blood stream.  As this treatment modality involves infusing fluid produced by the 
machine directly into the patient’s bloodstream, the quality of the purified water used 
for the substitution fluid needs to be ‘ultrapure’ i.e. injectable quality as defined by 
the European pharmacopeia.  
 
The first OLHDF clinical trial was performed in the mid-1980s with a customised 
prototype Fresenius A2008C dialysis machine.  This proved the feasibility, concept 
and potential of the OLHDF method  and over twenty five years later, ‘online HDF 
has proven to be safe, efficacious and with clinical benefits that justify it becoming a 
new standard for high-quality care of chronic kidney patients.’ (Bernard Canaud, 
2011).  
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2.7 Haemodialysis versus OLHDF - What are the experts currently saying? 
 
For the purpose of this literature review “Morbidity refers to the state of being 
diseased or unhealthy within a population,” while “Mortality is the term used for the 
number of people who died within a population.” (Rossi, Lipsey and Freeman, 2004) 
OLHDF first surfaced as a real alternative to traditional haemodialysis in the 1980’s.  
Initial thinking was that it would provide significant improvement to the outcomes and 
quality of life for long-term ESRD patients currently being treated by haemodialysis.  
The author has extensive national and international experience from an engineering 
perspective and has been involved from the 1990’s in studies and clinical trials of 
new prototype technologies, relating to adopting existing haemodialysis equipment to 
meet the stringent technical challenges of OLHDF.  The author will outline 
chronologically the perceived and proven beneficial benefits of this treatment versus 
conventional HD from all literature and introduce the latest iteration of this high-
volume OLHDF modality.   
 
In Montpellier France (B Canaud et al., 2000) published a reflective study of OLHDF 
versus HD over a thirteen year period involving 242 patients, with the aim of 
analysing the patients treated and its safety and adequacy as a treatment for ESRD.  
They concluded that this modality with the online production of substitution fluid 
offered a safe, efficient and economical means to treat chronic uraemia with a typical 
standard treatment session of four hours thrice weekly.  However, whilst the signs 
were encouraging it was too early to definitively comment, on a more ‘crucial 
concern of the nephrologist’, namely how effective is this treatment at preventing 
beta 2 microglobuin (ß2M) related amyloidosis? ß2M is strongly associated with the 
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presence of carpal tunnel syndrome and dialysis-related amyloidosis in chronic HD 
patients (Van der Weerd et al., 2007).  In a similar prospective randomised controlled 
trial (RCT) in Neuried, Germany (Ward et al., 2000) of 44 patients over a twelve 
month duration, it was concluded that while there was a superior solute removal over 
a wide molecular weight with OLHDF versus HD, the improved removal did not result 
in lower pre-treatment plasma concentrations. This may have been as a result of 
constraints with the mass solute transfer rates within the body.  Although these 
findings are significant, the sample size and study duration are limiting factors. 
 
In 2002, the results of the US-based HEMO study (Eknoyan et al., 2002), which was 
only the second RCT of the dialysis prescription on patient outcomes, the previous 
being the National Cooperative Dialysis Study (NCDS) twenty years beforehand, 
were published. This was a prospective RCT of 1846 prevalent patients comparing 
dialysis dose and high-flux with low-flux dialysis on patient’s mortality and morbidity. 
It involved 72 dialysis units and was the first randomised study on this subject as all 
previous similar studies were observational.  The study concluded that there were no 
beneficial outcomes for patients receiving thrice weekly treatments with a higher 
dialysis dose or from the use of high-flux dialysers when compared with current US 
directives.  (Cheung, 2003) concluded in a further observational analysis on the 
HEMO study that there may be greater benefit for patients who have had prior years 
of dialysis. This will need to be confirmed by another large randomised study.  In 
agreement with the author is an opinion article on the Hemo study, where it 
suggested that two potential flaws in this study were that of dialyser reuse and its 
influence, while noted as having a limited detrimental effect on ß2M clearance, was 
not considered and also that water quality was not taken into account.  (Levin & 
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Greenwood, 2003).   In additional opinion articles on the HEMO study from the US 
(Rocco, Cheung, Greene, & Eknoyan, 2004) and (Cheung et al., 2003) other 
fundamental parameters were not part of the study design and would require 
separate studies including for example, the effects of ultrafiltration and blood 
pressure control.  
Writing on the large European Dialysis Outcomes and Practice Patterns Study 
(DOPPS) (B Canaud et al., 2006) in relation to the mortality risks for patients 
receiving either OLHDF or HD, it was observed that OLHDF may improve patient 
survival independently of its higher dialysis dose but it was noted again that the 
potential mortality benefits of OLHDF must be tested by further clinical trials.  This 
study involved 4591 patients across five European countries.  In addition, (Rayner et 
al., 2004) stated that the results regarding mortality and morbidity in this study 
provide an important framework for future investigations that may lead to 
improvements in dialysis patient outcomes. 
(Schiffl, 2007) published the results of a German randomised controlled trial of a 
four-year duration with 76 patients and concluded that OLHDF and HD, both 
employing ultrapure water, offered sustained reductions in ß2M, however the 
reduction was more significant with OLHDF.  Also, removal of urea and phosphate 
was significantly greater for OLHDF.  It is noted at this time that the uptake of 
OLHDF is still quite low, but it is postulated that this will change once the results of 
on-going large scale studies become available.  Whilst the observational studies are 
reporting mixed findings in relation to the patient benefits detected regarding 
mortality outcomes, there is a total consensus with regard to the need for large 
randomised controlled trials as highlighted in numerous articles (Santoro et al., 
2008), (Feliciani et al., 2007) & (Vilar et al., 2009).  
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(Locatelli et al., 2009) Following a prospective randomised controlled trial of 648 
incident haemodialysis patients from 57 European centres, the Membrane 
Permeability Outcome (MPO) was published.   The MPO study looked at the survival 
rate of patients randomly assigned to low-flux or high-flux dialyses and having a 
serum albumin ≤40 g/l on enrolment.  One of the conclusions was that high-flux 
dialysis showed better survival rates in patients at risk for worse outcome, defined by 
serum albumin ≤40 g/l.  In a position statement on the MPO study (J. Tattersall et al., 
2009) stated that the study provided high grade evidence of improved survival for 
high risk patients i.e. serum albumin ≤40 g/l (grams per litre) using high-flux and also 
high grade evidence of  the beneficial effect on serum ß2M.  
The European Best Practice Guidelines (EBPG) guidelines of 2007 stated that use of 
synthetic high-flux dialysis membranes should be considered to delay long-term 
complications of haemodialysis therapy specifically relating to; dialysis-related 
amyloidosis, improved control of hyperphosphatemia, to reduce the cardiovascular 
risk and to improve the control of anaemia.  This recommendation was rated level 2B 
(weak recommendation) based on moderate quality evidence, for all patients. (J. 
Tattersall et al., 2007).  However, in light of the MPO study, combined with the 
subgroup analysis of the HEMO study, the European Renal Best Practice (ERBP) 
Advisory Board in 2010 issued a ‘position statement’ on the original EBPG 
specifically relating to guideline 2.1., in relation to the use of hi-flux dialysers to delay 
long-term complications in high-risk patients (serum albumin <40 g/l).  The rating 
was changed to level 1A (strong recommendation, based on high-quality evidence).  
Additionally, owing to the observation of reduced ß2M, the use of synthetic high-flux 
dialysers is recommended for low-risk patients at level 2B  (J. Tattersall et al., 2009). 
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From Thailand in South East Asia (Tiranathanagul et al., 2009)  results of a three 
year single-centre prospective observational non-randomised study  were published.  
Its purpose was to compare numerous patient outcomes of twenty two patients on 
HD versus OLHDF.  It concluded OLHDF was well tolerated with a lower incidence 
of intradialytic symptoms.  Additionally, they concluded an improved nutritional 
status, a lower inflammatory state and effective clearance of higher molecular weight 
toxins. As this study included only twenty two patients, its influence is lessened.  It 
was also non-randomised which can introduce bias (Britton et al., 1998), therefore its 
findings would require confirmation with a large ‘gold standard’ RCT.    
The Convective Transport Study (CONTRAST) was a RCT and involved 589 
patients in twenty six dialysis centres in three European countries (Penne et al., 
2010).  In its findings, using phosphate as the marker, it reported that pre-dialysis 
phosphate levels in patients dialysed with OLHDF compared with HD, were reduced 
which resulted in a decrease phosphate binder usage.  Whilst these results offer 
hope of improved patient outcomes in pre-dialysis phosphate levels and the 
associated potential cardiovascular benefits, the true benefit to improved patient 
mortality/morbidity outcomes, have still to be established. 
From 2010, the literature focused more on solute removal.  Increasingly, this focus is 
on the convective forces required and the volume of replacement fluid used in 
OLHDF to enable effective clearance of solutes with a medium to large molecular 
weight.  (Ledebo & Blankestijn, 2010) postulates that in order to get acceptable 
clearance of the medium and larger uremic solutes, it is not sufficient to rely on high-
flux membranes alone. In addition, we must add large amounts of convection by 
performing high volume OLHDF (HiVOLHDF).  This concurs with the DOPPS study 
which provided observational evidence as to the beneficial outcomes for patients 
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with a higher convection volume.(B Canaud et al., 2006).  A prospective Turkish 
RCT of 782 patients (Ok et al., 2012), agreed with the observational findings of the 
DOPPS study for patients receiving OLHDF with substitution volumes greater than 
17.4 L per session.  In an Italian prospective RCT study (Pedrini et al., 2011) 
involving sixty nine patients from eight centres randomly assigned to HD or OLHDF  
for six months, the findings concluded that when compared with HD, OLHDF may 
contribute to improved patient survival by  increased removal of  small and medium 
protein bound solutes.  This study, albeit small in the number of patients and short in 
duration, adds to the growing consensus relating to the potential benefits of 
HiVOLHDF.  However, as this study combined pre and post dilution (mixed dilution) 
for the substitution fluid, a direct correlation to the previous studies is not possible. 
(Pérez-garcía, 2014). 
While results of the further analysis of the  European CONTRAST prospective RCT 
of 714 patients (Grooteman et al., 2012) reported no significant survival benefits in 
patients treated with OLHDF versus HD, they did hypothesise on the perceived 
benefits on patient outcomes with total delivered convection volumes >20.7 L/ 
treatment, HiVOLHDF.  Again, it was recommended that this observation would 
require confirmation by further trials.  
(Maduell et al., 2013) and the Catalonian Estudio de Supervivencia de 
Hemodiafiltración On-Line (ESHOL) study was a RCT of 906 patients in 27 
Catalonian dialysis units,  with a remit to compare patient survival of OLHDF over 
standard haemodialysis and 456 patients versus 450 respectively.  The ESHOL 
study concluded that patients assigned to HiVOLHDF had a 30% lower risk of all-
cause mortality and a 55% lower risk of infection-related mortality when compared 
with patients who received standard haemodialysis.  They also concluded that this 
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would correlate to the possible prevention of one annual all-cause death by switching 
eight patients to OLHDF.  This was a relatively large RCT and of potential 
significance is the fact that the replacement volume of substitution fluid ranged 
between 20.8 to 21.8 litres per treatment session and possibly adds proof to 
previous studies relating to the importance of HiVOLHDF.  
 
(Mercadal et al., 2015) reporting on a French study of 28,407 patients 2008-2012 
from the findings of the French National Renal Epidemiology and Information 
Network’s (REIN) observational study of 28,407 patients were published in 2015 and 
concluded that the OLHDF therapy, compared to standard HD was associated with 
better patient survival, when accounting for all-cause mortality in the French patient 
population receiving one or the other of these treatment modalities.  A  prospective 
observational study in the UK (Davenport et al., 2015) of pooled data from 2753 
patients offered additional promise for the HiVOLHDF modality when the convective 
volume is individualised to the patient.  It concluded that while there appears to be a 
statistically significant reduction in all-cause mortality and morbidity with the cohort of 
patients treated with HiVOLHDF versus standard dialysis, further studies are 
required to consider individualised substitution volumes relating to patients BSA and 
weight.  Whilst all of the indicators are outlining the possible link to beneficial patient 
outcomes relating to morbidity and mortality when treated by HiVOLHDF, this is very 
encouraging and offers promise, the science is still not totally conclusive.  Further 
large RCT’s to prove and consolidate the emerging evidence on the effect of 
HiVOLHDF in improving patient survival are required. (Locatelli, Violo, Longhi, & Del 
Vecchio, 2015).   
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While the evidence may not be totally complete regarding HiVOLHDF, in the 
meantime a reflective article by Canaud should be considered; “So why not offer 
OLHDF to all end-stage kidney disease patients?  It is a promising wager on a future 
of renal replacement therapy with improved patient survival and enhanced quality of 
patient life.” (Bernard Canaud, 2011). 
 
2.8 Implications for the project 
 
Whilst we currently do not have complete consensus regarding the beneficial 
morbidity/mortality outcomes for patients being treated by HiVOLHDF, it is the 
author’s belief that it is only a matter of time before this evidence will be available.  In 
the meantime, it should be considered best practice to strive towards implementation 
of ultrapure water.  Achieving water of the best quality possible, namely ‘ultrapure 
water’, should be the standard specification for all new dialysis units in 2016.  For the 
scope of this project, that is the specification that is been used (J. Tattersall et al., 
2009).  While this offers an additional complexity to the design phase and certain 
additional cost, this is offset by the fact that the system has a degree of future 
proofing for any revision to quality standards which may occur.  With the capital 
expenditure required when installing a new water purification plant for dialysis, which 
is typically a twenty year investment it seems prudent that the best possible 
specification of the day is used especially whilst been aware, that regulatory 
standards for online haemodialysis therapies are almost certainly going to become 
more stringent and obligatory.  (J. E. Tattersall & Ward, 2013).  
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2.9 Summary and conclusion 
 
Although the nephrology world is not still totally convinced by proven factual data, it 
would appear that HiVOLHDF has the potential to offer scientifically proven, 
significantly better patient outcomes in the near future.  In this context, one must be 
cognisant of the fact that at the heart of the dialysis process is the water purification 
system.  Its design and specification will have implications regarding the future 
dialysis modalities a hospital can offer, in the short, medium and long term.  In this 
context, it is financially prudent to invest in the best possible system when 
purchasing new water purification equipment, that meets all current and any 
proposed future standards, as such capital reinvestment may take twenty years to be 
readdressed. 
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3. Methods and methodology 
 
“There is nothing more difficult to take in hand, more perilous to conduct, or more 
uncertain in its success, than to take the lead in the introduction of a new order of 
things.” (Machiavelli, 1532). 
 
3.1 Introduction 
 
In this chapter the author will introduce and explain the various approaches to 
organisational change.  This will involve discussing the various models that exist and 
their particular characteristics, merits and demerits. Following this, the subjects of 
organisational culture, resistance and the importance of leadership will be introduced 
and discussed.  In the next section, the rationale for the selected change model for 
this organisational change project will be discussed and the various phases defined 
in the context of this organisational development.  
 
3.2 Approaches to Organisational change  
 
Various models exist which can provide a logical process to guide one through the 
process of change.  One must be cognisant of the fact that there is not a one size fits 
all in relation to organisational change.  The change agent/leader must be cognisant 
of the distinct factors within change namely planned, emergent and spontaneous 
change and be adaptable to change and flexibility within the change process.  
Planned change traditionally follows a rigid set of interconnected steps in a strict 
almost choreographed order.  Planned change rarely achieves a radical cultural or 
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systemic change within an organisation, and is often referred to as been ‘structural 
change’. Emergent and spontaneous change generally exude a nonlinear, flexible 
approach and with numerous concurrent components.  It is the authors opinion that 
there is an analogy between planned/emergent change and 
transactional/transformational   leadership styles.  In order to enact successful 
change the leader must adapt to prevailing changes and circumstances to achieve 
the vision and aim within the organisational context, which may be a 
reconceptulisation of the historical definition of leadership (Liebhart & Garcia-
Lorenzo, 2010).  The leader must exhibit and perform the best attributes of all the 
current leadership skills, which will be further addressed in section 3.3 and in relation 
to this organisational development in 3.4. 
3.2.1 Lewin 
In the 1950’s Kurt Lewin a physicist and social scientist explained the process of 
organisational change by using a quite simplistic analogy to changing the shape of a 
block of ice.  This process known as the Lewin model consists of three distinct 
phases.  Phase one is called the ‘unfreezing’ phase and this is where there is 
admission that a process or system is not efficient and requires changing.  This is 
the phase where all influencing factors are considered, especially factors which may 
hinder or obstruct the process and thereby the potential of the change 
implementation. Lewin considered communication to be very important to 
successfully unfreeze the existing conditions and to highlight the discrepancies 
between the current and desired future state. (McAuliffe & Vaerenbergh, 2006). 
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Phase two of this process is known as the ‘Change’ phase and is where the 
organisational change is implemented. This can be the most precarious phase.  To 
use the ice analogy, this is where the process is in liquid form and where the process 
can unravel.  The final phase is what Lewin called ‘Refreezing’ where the change 
has been enacted and incorporated into the daily way of business.  
3.2.2 Kotter 
This model consists of eight distinct steps which can be divided into three distinct 
groupings namely ‘creating a climate for change’, ‘engaging and enabling the whole 
organisation’ and finally ‘implementing and sustaining change’. Within the first 
grouping the stages are firmly based around the foundations; ‘creating a sense of 
urgency’, having a ‘guiding team’ and having the ‘uplifting vision’.  The urgency, 
guiding team and vision combined add dynamism to the organisational change and 
create the bedrock for the subsequent groupings.  The second grouping again 
comprises of three distinct stages namely; ‘communicate for buy-in’, ‘empower 
action’ and ‘create short-term wins’.  All this builds on group one and consolidates 
the complete process. Excellent communication combined with empowerment and 
short term wins makes the ultimate goal more achievable and attainable.  
Communication must be clear, heartfelt, concise and accurate, not complex and 
technocratic.  This has the effect of diminishing fear and mistrust. (Kotter & Cohen, 
2002).  The final grouping in Kotter’s organisational change model comprises two 
stages ‘don’t let up’ and ‘make change stick’ and has similarities with Lewin’s 
refreezing stage. Its importance cannot be understated in order to prevent the 
implementation unravelling. The organisational change must be embedded into the 
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culture of the organisation for change to succeed and its implementation will then 
become firmly the new normality. (Kotter & Cohen, 2002). 
3.2.3 Senior and Swailes 
Barbara Senior and Stephen Swailes developed their five stage model in 2010 and 
describe projects as been ‘Hard and difficult’ or ‘Soft and messy’. ‘Hard’ projects are 
described as being tangible, easily defined and for which a logical solution generally 
exists. On the other hand  ‘Soft’ projects are more difficult to define and are less 
tangible and hence ‘messy’ (Senior, 2002).  Stage one of this model involves two 
phases, diagnosis of the present situation and a vision development to get to the 
future state by change. 
 
They use the Paton and McCalman from 2000 TROPICS rating (timescale, 
resources, objectives, perception, interest, control and source) to quantify the scale 
of the problem.  The remaining four stages involve ‘gaining commitment to the 
vision’, ‘developing an action plan’, ‘implementing the change’ and finally ‘assessing 
and reinforcing the change’.  The Senior and Swailes model is active and employs a 
continuous feedback mechanism between all stages unlike the passive Lewin and 
Kotter models. 
3.2.4 Health Service Executive (HSE) Change Model 2009 
This organisational change model comprises of four distinct phases with seven 
separate steps.  The initiation phase is the preparatory phase and involves the 
leader determining the key components of the organisational change e.g. defining 
the aim and objectives, identifying all stakeholders, determining the urgency and the 
resources required.  It is at this initiation phase that the business case is developed. 
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Planning is the second phase and involves ‘building commitment’, ‘detailing the 
change’ and ‘developing the implementation plan’.  In building the commitment the 
leader is selling the vision to stakeholders and staff.  Unrelenting communication is a 
fundamental requirement to achieving total commitment.  A communication plan 
should be established to facilitate this. (HSE, 2008).  By ‘determining the detail of the 
change’ the leader and key stakeholders clearly outline the precise specifics for the 
required change. By having the key stakeholders and staff involved at this early 
stage facilitates maximum buy-in.  The final step of the planning phase involves 
developing the implementation plan.   
 
The third phase of the HSE change model is the implementation phase consisting of 
a single step, namely ‘implementing change’. This is where the change is enacted 
and we transition from the old to the new way of doing things.  Yet again, 
communication is critical for the leader and the team to successfully achieve the aim 
and objectives.  Leaders must be adaptable and open to fine tuning actions as 
dictated by the prevailing conditions.  It is the leader’s responsibility to keep the 
agreed vision on track and within the agreed resources.  
The final phase consists of two steps and is known as ‘Mainstreaming’. By ‘making it 
the way we do business’ we are normalising the new reality and we embed the 
change into the new organisational structure. It is important that the leader is 
observant of the achievement by all, and that time is taken to celebrate this.  This 
should be the case at ‘all stages and key milestones’.   Finally, with the ‘evaluating 
and learning’ step is the opportunity to assess the effectiveness of the organisational 
38 
 
change and its implementation.  Fine tuning may be required to ensure a live change 
is implemented efficiently, from the theoretical change outlined pre implementation. 
3.2.5 Critical review of organisational change models 
 
“When you're finished changing, you're finished.” Benjamin Franklin 
 
In  2005, in a critical review of change management argues that the fact that up to 
seventy percent of all change management initiatives fail (Balogun & Hope, 2008), 
may be as a result of the fact that there is a lack of a valid framework or model.  It 
goes on to criticise the available models as being based on “unchallenged 
hypotheses and lacking empirical evidence”. (Todnem By, 2005).  In a 2015 review 
Bartunek and Woodman discuss the increasing complexities relating to 
organisational change models when compared to Lewin’s model, as it approaches 
seventy years since its development.  They describe Lewin’s model as having 
isolated phases with no interconnection or feedback.  Using an orchestral analogy, 
they compare the monophonic Lewin’s method with current organisational change 
which has evolved into a complex polyphonic process.  To reflect this evolution, 
change models need to move away from the linear three step model outlined by 
Lewin into a broader interlinked, temporal model with iterative components. 
(Bartunek & Woodman, 2015). 
 
In relation to Kotter’s model, Appelbaum et al in 2011 revisited John Kotter’s 1996 
change model in an attempt to ascertain what the pros and cons of each of the eight 
steps are and concluded that whilst it is a good starting point, it’s rigidity regarding 
following the steps in sequence was negative.  They suggested that it may be best to 
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use in conjunction with other models. (Appelbaum, Habashy, Malo, & Shafiq, 2012).  
While Kotter’s model has been one of the most widely used it lacks academic 
literature that analyse its use in practice. This model is often portrayed as a linear 
sequence of steps but (Pollack & Pollack, 2014) state that to manage anything but a 
small organisational change requires “the change team to facilitate multiple 
concurrent instances of Kotter’s process throughout the organisation”. (Pollack & 
Pollack, 2014).     Pollack, in a research article on the Kotter model indicates that a 
disconnect exists between the change management academia and the practitioners 
of change.  The academics emphasis was based on theory, models and frameworks 
while this was not apparent with the change practitioners. This was based on a 
three-stranded study; ‘an analysis of highly cited change management articles, most 
cited articles in the specialist change management publications and interviews with 
change management practitioners.’(Pollack, 2015). 
 
Similarly, in a 2015 article by Mark Hughes he states that both Kotter’s article and 
book would ‘have gained legitimacy’ if they had been backed up by research.  He 
goes on to say that whilst Kotter’s book ‘Leading Change’ remains a testament to 
leadership studies, it is out of date and “paradoxically today discourages change”.  A 
disconnect between leadership studies and practice is alluded to by Hughes and is 
described as needing to be challenged. (Hughes, 2015). 
 
3.3 Change Leadership, Resistance and Culture  
 
The key attributes of a leader who is embarking on an organisational change are 
persuasion, trust, emotional intelligence (EI), vision, a sense of urgency and a 
dedication to the vision. (Garvin & Roberto, 2005) & (Appelbaum, Degbe, 
40 
 
MacDonald, & Nguyen-Quang, 2015b)  Stonehouse 2013 highlights the importance 
for the change agent, to be seen to have the managers’ support and the 
organisations buy in where possible right to CEO level. (Stonehouse, 2013).  In 
relation to persuasion, in separate articles Cialdini & Conger refer to persuasion as 
having scientific and artistic components respectively.   Furthermore the scientific 
component is described as been a cocktail of six parts namely; liking, reciprocity, 
social proof, consistency, authority and scarcity. (Cialdini, 2001). Similarly, the 
artistic element is described as having the following stages for the effective change 
agent; establishing credibility, framing the vision, providing evidence to substantiate 
the vision and finally, the change agent must connect emotionally.  (Conger, 1998).  
Whilst the aforementioned attributes are essential for the change agent to enact a 
successful organisational change, it is the author’s belief that trust and EI provide the 
foundation.  In order to avoid the possible deceptive or coercive influences of the 
scientific and artistic components, trust can be the guardian.   
 
Writing in the Harvard Business Review Jeanie Daniel Duck emphasises the 
importance of trust within change management, and alludes that this needs to be 
established prior to change enactment as it is more difficult to establish in the midst 
of change. (Duck, 2000). In addition, the change agent is required to be politically 
astute. By being astute, an individual shows an understanding of others actions and 
their motivations. Therefore a politically astute person is a person who is aware of 
the political dynamics within an organisation and of the external influencing effects.  
They knowledge is not used in a manipulative manner or for personal gain, but for 
the overall benefit of the team’s, or the organisation’s goal or vision. (Hartley, Alford, 
Hughes, & Yates, 2013).  The leader must be cognisant of power which can have the 
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following manifestations, coercion, manipulation, domination and subjectification.  
“Power not only represses and controls, but also produces behaviour both desirable 
and undesirable, depending on the political lens through which one views it.” 
(Fleming & Spicer, 2014) &  (Senior, 2002). In order to effectively achieve successful 
management of change, the leader must be aware of the organisational context 
within which they are trying to implement the change, whilst been totally cognisant of 
their personal leadership style and the necessity of changing from transformational 
(Phipps, Prieto, & Verma, 2011) and transactional in sympathy with the prevailing 
circumstances of the change cycle. (Appelbaum, Degbe, MacDonald, & Nguyen-
Quang, 2015a). & (Ford, Ford, & D’Amelio, 2008). 
 
For many resistance tends to conjure up negative connotations. The change agent 
should consider countering this by considering it as a potentially powerful resource to 
validate and fine tune the vision.  Resistance to change should not be construed as a 
negative or an obstructive force by the change agent but rather as a strengthening 
attribute for the change process, and a self-check for the leader/change agent.  
Resistance, albeit with negative connotations, should be considered as something 
more dynamic and positive and, as described by Ford et al should consist of three 
components, namely ‘change recipient action’, ‘change agent/leader sense-making’ 
and lastly ‘change agent recipient relationship’. It is recommended that the leader 
should lead the conversations and communicate effectively to identify the root of 
possibly misplaced or perceived resistance (Ford et al., 2008). Resistance can stem 
from genuine concerns within an individual or group, internal or external and the 
successful change agent should embrace and use as leverage to improve overall 
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commitment to the change rather than use it as a criticism of perceived opponents. 
(Appelbaum et al., 2015a) &  (Ford et al., 2008).   
In an interesting article on organisational culture in relation to healthcare 
performance, Scott et al. 2003 postulate that the intricacies of culture and 
performance require further conceptual and empirical work to determine the true 
definition of both concepts and their true interdependencies. (Scott, Mannion, 
Marshall, & Davies, 2003).  From a national study of clinical governance managers in 
acute and primary care trusts throughout England, Mannion et al. comment that 
whilst there are an overabundance of culture assessment tools they tend to be 
predominately focused on the assessment of safety cultures rather than quality and 
performance. (Mannion, Konteh, & Davies, 2009).  In a special article Davies et al. 
observe that the roots of organisational culture has its roots in ‘anthropological 
literature’ and that organisational culture evolves from shared beliefs, values, 
attitudes and goals between colleagues from within an organisation. (Davies, Nutley, 
Mannion, & Davies, 2000).  
Organisational psychologists Weick and Quinn compare and contrasts ‘episodic’ and 
‘continuous’ change methodologies and their impact. Episodic organisational change 
tends to be infrequent and only happens sporadically within an organisation.  From 
the current equilibrium, a change is applied to reach the desired vision, the new 
equilibrium. This category is generally very closely aligned with Lewin’s three stage 
change model.  By contrast ‘continuous’ change, as the name suggests, is an on-
going process.  This type of organisational change can benefit from the synergy of 
cumulative, concurrent small changes. Organisations which operate in this manner 
are in a continual state of mini change. (Weick & Quinn, 1999).                         
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3.4 Rationale for the selected change model 
 
The HSE Change model (figure 5) was selected for this organisational development 
project as it was deemed the best fit for a development of this scale and as it 
facilitates numerous episodes of change. This model incorporates a nonlinear 
cyclical approach and treats the process in an adaptive manner. It recognises that 
the Irish health services are involved in a perpetual process of change at all levels 
and also facilitates multiple instances of concurrent change.  The model is based 
around best practice and is evidence based.  As mentioned in section 3.3 there are 
key attributes that the change agent  must exhibit in order to successfully enact a 
change, in addition he/she must be cognisant of the various components involved in 
the organisational development; people, culture, structures, processes, 
organisational and individual behaviours. (HSE 2008).  As a means of a reminder, 
the existing dialysis unit is not fit for purpose from numerous critical aspects.  While 
the water quality is sufficient for standard and high flux dialysis the existing 
purification equipment does not have the capability of meeting the stringent 
requirements proven as necessary for HiVOLHDF without been totally dependent on 
the on-board additional filtration of the dialysis machine.  In addition, the current 
environment is not best suited to the treatment of dialysis patients in a setting that is 
in sympathy with best care surroundings.  Finally, the current facility does not comply 
with best practice guidelines for the treatment of isolated patients, accreditation and 
fire regulations. The HSE change model and some of its parts will now be applied to 
this organisational development with its various instances of concurrent change. 
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Figure 3 
 
3.4.1 Initiation 
‘Preparing to lead the change’ 
The objective of this stage was to scope out the scale of the organisational 
development, add flesh to the vision and make it a tangible potential reality as 
opposed to a theoretical concept.  
The author performed a force field analysis (figure 4) to determine the scale of the 
forces supporting and opposing the changes.  Lewin developed his force field theory 
as an assessment tool to highlight the driving and resisting forces for the change 
initiative and with this tool the leader is better equipped to implement the 
organisational change.   
45 
 
Figure 4 
The force field analysis showed significant supporting forces, predominately from 
within the organisation but most importantly from the HSE and the National Renal 
office.  The main potential for resistance was identified as being the current 
occupants of the identified preferred location namely the pre dialysis and peritoneal 
dialysis services.  Whilst the scale of this resistance was numerically small when 
compared with the supporting forces, it was still significant and required close 
management and monitoring by the change agent.(Ford et al., 2008).  A secondary 
channel of resistance emerged during this initiation phase when the proposed 
location for the water purification plant room met with opposition as this location had 
been assigned previously for the ICT servers.  
The author focused on these potentially very significant restraining forces to reduce 
their impact.  This was achieved by negotiation during a series of separate meetings 
with the ICT department and the pre dialysis and peritoneal dialysis services.  In 
relation to the ICT requirements, numerous possibilities were explored 
unsuccessfully but with the change agents further exploration and intervention, a 
larger more suitable location was identified and agreed upon on a different floor 
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within the block.  This location surpassed the current ICT requirements but also 
facilitated a degree of future proofing to meet and host future expansions.  In relation 
to the relocation of the CAPD and pre-dialysis services this was harmoniously 
enabled by the relocation to the refurbished and partially vacant St Monica’s ward. 
Following the force field analysis, the author performed a stakeholder analysis, 
(appendix 1) in order to identify the range of stakeholders, both within the 
organisation and external to it.  The stakeholder’s power and influence were 
determined in order to highlight their impact on the project and its implementation.  
This enabled the author to develop the most appropriate communication avenues 
from the beginning thereby developing relationships and facilitating stakeholder buy-
in from the outset.(Fleming & Spicer, 2008). 
The author analysed the various stakeholder groupings and developed a 
communication strategy around this. Meetings were scheduled commencing with the 
low interest high influence group.  The author deemed this necessary because whilst 
their interest was low their influence within the organisation may prove very 
important particularly in relation to unseen resistance. Communication involved 
sharing the vision and the proposed implementation programme.  With regards to the 
high interest/low influence group communication was channelled through existing 
established forums.  For instance, the project updates were included on agendas of 
the regular nephrology management team meetings and the clinical engineering 
department meetings. In relation to the high interest/influence stakeholder’s 
communications during the initiation stage, these were frequent and formal.  It 
involved  using Ancona's four components of leadership, 'sensemaking ', 'visioning ', 
'inventing ' and 'relating' (Ancona, Malone, Orlikowski, & Senge, 2009)  in  order to 
prepare for the planning and implementation stages.  Finally, the low 
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interest/influence group were then defined as requiring, minimal but important key 
communications, as this group may transition to high interest and then potentially 
high influence in the later stages of planning and implementation. This transition will 
potentially manifest itself once the successful initiation phase is complete. A PESTE 
(Political, Economic, Social, Technical, Environmental) analysis is a powerful 
framework or tool that the change agent/leader can use to assess influences and 
their importance relating to a change management project and its implementation.  In 
the initiation stage of an organisational change project, current thinking is that best 
practice is to perform a PESTE analysis and allow this to feed into the threats 
section of the SWOT analysis (Strengths, Weaknesses, Opportunities & Threats). 
(Jacobs, van Witteloostuijn, & Christe-Zeyse, 2013). 
In relation to this organisational development project the PESTE analysis and its 
relevant influences/challenges are as follows: 
• Political influences: If these are not managed there is risk of failure to get 
approval to relocate to the required locations 
• Environmental: The proposed water purification system as mentioned will be a 
dual reverse osmosis system with the capability of operating in a duty standby 
configuration if required.  It will offer economies in water usage as RO1 waste 
is recycled and feeds RO2 and this will result in a 15% reduction in total water 
wastage.  As mentioned, the system will perform heat sanitisation thereby 
reducing the routine use of caustic chemicals.  In addition, a centralised 
concentrate delivery system (CCDS) will eliminate the current use and 
disposal of 6 litre polyethylene canisters. 
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• Social: For the scope of this organisational development the proposed social 
change will mean that patients will be treated in a new state of the art modern 
facility. 
• Technical: Technologically, this project proposal will present many challenges 
in order to achieve the water quality specification required to offer the 
preferred treatment modality HiVOLHDF.  In addition, there will be technical 
challenges while trying to implement the best patient environment within the 
proposed location. 
• Economic: Failure to get approval for funding of the infrastructural works and 
the high specification water purification plant. 
SWOT (appendix 3) 
• Strengths: This project offers the capability to perform HiVOLHDF in a fit for 
purpose environment while achieving patient isolation requirements. 
• Weakness: There is a possibility of not expanding the facility sufficiently to 
future-proof for service requirements. 
• Opportunities: The opportunity to create a state of the art haemodialysis unit 
offering HiVOLHDF as the optimum treatment. 
• Threats: The proposed location is currently occupied by the PD and pre-
dialysis services.  There may be resistance to the relocation of these services.  
There is also a potential threat relating to the proposed location for the water 
purification plant. There is a dependence on the external political environment 
in relation to funding.  
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During the course of this project, a new potential threat emerged.  One of the key 
internal stakeholders left the organisation which left a significant void in relation to 
implementation of this organisational development, potentially it could have 
‘unfrozen’, lost impetuous and unravelled.  For the change agent, this required 
revisiting the SWOT and stakeholder analysis specifically relating to threat 
(appendices 2 & 4).  This potential threat did not materialise, however it does 
highlight the importance for the change agent/leader being cognisant and responsive 
to all perceived and actual threats and adjusting the programme and his/her 
leadership style accordingly. 
3.4.2 Planning 
The planning phase of this organisational development was multi factorial and 
involved all three steps of this phase of the HSE model i.e. ‘Building commitment, 
determining the detail of the change and developing the implementation plan’ (HSE 
2008).  
In order to gain and ‘build commitment’, the author engaged with the key 
stakeholders in the previously defined high influence/interest group. In addition, the 
high influence low interest group were included as their influence was critical to 
ensure corporate and financial commitment at this critical juncture.  This was 
achieved by a combination of one-on-one and group meetings where the vision was 
reiterated and the projected implementation outlined.  Also, these meetings offered a 
forum for the change agent to voice any significant developments or concerns 
relating to the progression of the organisational development.  These meetings 
proved extremely beneficial for the change agent, when in particular confronted with 
the previously mentioned potential threat to the project from the departure of a key 
internal stakeholder.  It was through this medium that this individual’s responsibility in 
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relation to the project was transferred to another key stake holder, who already had 
high interest but low influence in the project. Appendix 4. 
In ‘determining the detail of the change’ the author was predominately involved with 
the engineering specification of the technological requirements to ensure the reliable 
routine production of ultrapure water.  This involved the lead clinical engineer for 
dialysis, the technical services department and the water purification equipment 
vendor.  During this series of meetings, the details of the proposed technical solution 
were discussed, fine-tuned and advanced towards a final solution.  This group were 
particularly cognisant of the limiting infrastructural restrictions which prevailed, owing 
to the fact that the intention was to retrofit this modern system within an existing 
functioning hospital.  The logistical aspects of this will be addressed in the next 
paragraph.  The change agent was also involved in planning the transfer of the 
existing service to the new facility.  This involved initial exploratory meetings with the 
nephrology team (both medical and nursing), clinical engineering, portering and 
security.  From these initial meetings the consensus was to plan for a phased 
transfer. To this end, it was agreed once go live date was agreed the second 
treatment of that day would be performed in the new unit.  This approach offered 
numerous benefits; firstly, pressure on commencing all treatments at 8am was 
abated, offering the opportunity to meet, assess and debrief on the effectiveness of 
the change. Finally, it afforded the opportunity to provide full technical assistance for 
the phased trial transition.   
‘Developing the implementation plan’ provided the change agent and stakeholders 
the opportunity to focus on the details of the infrastructural redevelopment and its 
schedule, the water purification plant installation programme and the transfer of 
services in a coordinated manner.  From the change agent’s perspective, at this 
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point the water purification vendors had traversed to the status of high 
influence/interest, in the stakeholder’s analysis, as their installation plan would 
directly influence the key milestones in relation to the new unit going live.  Their 
schedule of work necessitated out of hours and weekend work owing to the fact that 
these works had to be completed in a live functioning hospital.  Significantly and 
importantly, this did not accrue any additional expenditure as it had been clearly 
highlighted in the initial scope of works within the specification document.  In 
conjunction, the change agent was actively engaged with the key stakeholders in 
relation to the physical logistical transfer of services from the existing unit to the new. 
This engagement was deemed essential at this stage by the change agent in order 
to alleviate or address any potential issues.  
As stated and demonstrated, the HSE change model readily facilitates multiple 
concurrent changes within the remit of a singular organisational development. Whilst 
it is achievable, it requires flexible, adaptable, hands on approach by the 
leader/change agent.  He/she must be prepared to continually revisit, reassess, and 
alter as necessary to progress the vision and ensure there is a readiness for the 
change.(Rafferty, Jimmieson, & Armenakis, 2012). 
3.4.3 Implementation 
The implementation phase for this particular organisation development consisted of 
three distinct but closely interlinked components; the infrastructural redevelopment, 
installation of the water purification plant and the transfer of the existing dialysis 
service to its new location.  The author shall now outline the implementation of these 
components, highlighting overlap and interdependencies as appropriate. 
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The infrastructural redevelopment 
As with any medium to large size construction project within a live functioning 
hospital, there are numerous safety and environmental concerns.  A major benefit to 
this project was that this component was coordinated through the organisations 
technical services department (TSD), so no third party contractors had to be 
managed.  The site was locked down and isolated from the main hospital for the 
demolition phase of the works in late August 2015. This required significant alteration 
to existing wayfinding on a temporary basis.  Additionally, a separate entrance to 
facilitate the ingress and egress of construction personnel and materials was 
created.  The primary role of the change agent during this stage was to monitor the 
progress of the redevelopment in relation to the predefined plan.  This was achieved 
by having regular meetings with the assistant head of technical services who project 
managed the redevelopment.  This close collaboration was essential in order to 
achieve the overall implementation on target with the agreed schedule.  One 
potentially very significant matter arose in relation to the delivery and installation of 
the high-efficiency particulate arrestance (HEPA) air handling unit (AHU).  The AHU 
was to be manufactured near Frankfurt in Germany and was due for delivery and 
installation mid-October. However, owing to a communication breakdown this was 
not achievable and estimated installation had to be rescheduled for mid-November.  
The significance of this was that it directly impacted on the validation schedule of the 
water purification plant, pushing out the go-live date to March, which would directly 
impact on plans for the vacated old dialysis unit.  Following a series of meetings, this 
issue was alleviated with a compromise solution.  All of the enabling works for the 
installation of the AHU would be completed as per schedule and capped off in the 
ceiling void and a new location for the installation of the AHU was located and 
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agreed.  This compromise solution facilitated the scheduled water plant 
implementation as planned and did not impact on the HEPA air quality.  While this 
example demonstrates the importance of adaptability and flexibility, it also 
demonstrates the necessity for the change agent to keep to the agreed deadlines in 
achieving the shared vision. 
Installation of the water purification plant 
Once the demolition stage of the infrastructural redevelopment and the rebuilding 
phase had started, the initial stages of the water plant installation commenced.  
Many stages of these two critical components of the organisational development 
were performed simultaneously and were interdependent.  The highly specialist 
nature of the water plant installation was managed directly by the equipment 
manufacturer Whitewater.  Stage one of the water plant installation involved 
assembly of the plant in its dedicated plant room which is situated adjacent to the 
dialysis unit.  This was scheduled to be completed over six weeks and was 
completed within this timeframe.  Following this, the Clean-PexTM circulating ring 
main was installed. This circulates the ultrapure water to the dialysis media panel 
(DMP) at each treatment bay.  The DMP is a service delivery panel which facilitates 
the delivery of electrical power, ultrapure water, data and dialysis concentrates. This 
is currently considered best practice from both an aesthetic and ergonomic 
perspective.  This was followed by the commissioning of all the individual plant 
components of the purification process and then the complete system.  Once 
commissioned, the intensive period of heat disinfection of the complete ring main 
commenced, followed by the detailed quality validation.  Again the role of the change 
agent was to monitor the progress of all components in line with the project plan.  
This required detailed analysis of the scheduled works in relation to key milestones.  
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With respect to the CCDS and its installation, it became apparent in late October that 
this would not be achievable within the timeframe of this development.  This resulted 
from a manufacturing fault identified by the manufacturer Fresenius Medical Care 
(FMC) which impacted the manufacture of all CCDS systems.  FMC notified their 
client, this organisation, that the new estimated delivery would be January 2016.  
Following meetings with FMC, Whitewater and TSD it was agreed to proceed with 
CCDS ring main installation and connection to the DMP’s.  This would facilitate a 
minimally intrusive installation of the CCDS on a Sunday after the new dialysis unit 
went live.  It would also negate the need for a deep clean of the unit post installation 
of the CCDS as there would be no requirement to enter the roof void or the DMP’s.      
Transfer of the dialysis service 
As mentioned in the planning phase a ‘trial transfer’ was agreed with all the relevant 
stakeholders prior to the complete transfer of the service.   This involved the 
nephrology team, clinical engineering, portering and security but in addition at this 
stage dietetics, catering and pharmacy were also included.  It was deemed prudent 
at this stage to include these additional service providers to gain reassurance that 
the relocation from a practical perspective did not present any unforeseen issues for 
the provision of their services.  The trial was agreed for the second set of treatments 
on February 9th 2016 with a complete transfer of services scheduled for the 11th, 
subject to a satisfactory trial.  At a meeting on the 10th it was agreed that the trial had 
been a resounding success and presented no impediment to the scheduled 
complete transfer of services the following day.  As planned, all the new dialysis 
machines were transferred from the existing unit at the end of treatment on the 10th, 
and reprogrammed for automated heat sanitisation to commence before the unit 
opened on the 11th.  This is performed in addition to the weekly pre-programmed 
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automated disinfection of the ultrapure water ring main.  With the service now 
successfully transferred to its new location with its dedicated isolation facility and 
HiVOLHDF with ultrapure water a reality, the author formally handed over the day to 
day running, from a technical perspective, to the lead clinical engineer for dialysis 
services.  For the departments of nephrology, clinical engineering and the 
organisation, this is the ‘new way we do our dialysis business’. 
3.5 Summary and conclusion 
The author used the HSE change model for this organisational development as it 
provides a logical approach during the process, while affording the change leader 
certain flexibility when compared with the more regimented and linear Lewin and 
Kotter models.  It is a cyclical model which benefits the change agent as one can 
move back and forth between stages.  There were numerous challenges to this 
change project owing in part to its highly technical nature, its three distinct 
components as highlighted in 3.4.3 but also the array of stakeholders both internal 
and external.   
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4.0 Evaluation 
 
““The only man who behaves sensibly is my tailor; he takes my measurements anew 
every time he sees me, while all the rest go on with their old measurements and 
expect me to fit them” 
George Bernard Shaw 
4.1 Introduction 
 
This chapter will focus on the evaluation of the implementation of this organisational 
change project and will comprise two distinct components; the quantitative analysis 
of the production of ultrapure water and the development of a KPI and secondly, the 
qualitative analysis from the patients’ perspective on their experience of the new 
versus the old unit. Firstly, the author will outline the background to healthcare 
evaluation and introduce some frameworks. In addition, the aim and objectives of 
this organisational change project will be revisited and discussed. This will be 
followed by a detailed explanation of the evaluation results of this organisational 
change. Finally, this chapter will conclude with a summary of the evaluation and a 
reflection on the chosen methodology.   
4.2 Evaluation and Healthcare 
 
As alluded to in chapter three, all aspects of Irish healthcare are in a continuous 
state of concurrent change.  This is again multi-factorial, with numerous 
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predominately positive aspects e.g. technological advances, socio-political 
influences, and financial constraints and despite current public opinion, the 
continuously improving services which facilitate better patient outcomes.  To 
embrace and enact these changes successfully requires evaluation, ensuring the 
patient experience is therapeutically beneficial and delivered in a sympathetic caring 
environment, with patient satisfaction to the fore (Conry et al., 2012) & (HSE, 2008).  
As a result of historical inconsistencies in the delivery of care, the need for 
evaluation and standardisation of practice based on these evaluations is now of 
paramount importance.  As recommended by the HSE evaluation should be 
resourced and funded correctly for all stages of the change programme. (HSE, 
2008). 
4.3 Evaluation Frameworks 
An evaluation programme is a logical systematic process used to assess the 
effectiveness of a project or programme, from the inception stage to the completion 
stage. It can be an iterative process requiring the evaluator to continually assess and 
modify the process to achieve the desired aim and objectives.  According to Rossi, 
Lipsey and Freeman (2004) the following distinct stages may be involved, which may 
also require different evaluation methodologies and the evaluation may be 
conducted at several stages during a project’s lifetime.  
 Assessment of the need for the programme 
 Assessment of the programme design and logic/theory 
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 Assessment of how the programme is being implemented (i.e., is it being 
implemented according to plan? Are the programme's processes maximizing 
possible outcomes?) 
 Assessment of the programme's outcome or impact (i.e., what it has actually 
achieved) 
 Assessment of the programme's cost and efficiency 
(Rossi, Lipsey and Freeman, 2004) 
There is a whole array of evaluation frameworks e.g. the ADDIE, DECIDE, ‘Logic 
framework’, the CIPP (Context, Input, Process and Product), Kirkpatrick’s and the 
Miller framework.  Most of the frameworks have evolved from three theories namely; 
system, complexity and reductionism. These theories assist the evaluator when 
selecting a framework.  There is no hierarchy a of good or bad framework and it is 
best to select an evaluation framework that is most suitable for the particular project. 
(Frye & Hemmer, 2012). In some instances, it may be more appropriate to combine 
components from different frameworks depending on the particular nature of the 
evaluation. 
It is the authors opinion that the DECIDE framework offers a concise and meaningful 
introduction to the whole concept of evaluation in the context of an organisational 
development. This framework consists of six steps which are defined as follows: 
● Determine the aims and objectives the evaluation addresses 
● Explore the specific criteria to be answered 
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● Choose the evaluation paradigm and framework or frameworks to answer the   
criteria 
● Identify the practical issues 
● Decide how to deal with the ethical issues 
● Evaluate, interpret and present the data    
4.4 Aims & Objectives 
 
As outlined in chapter one the aim of this operational development is to relocate and 
expand the existing acute inpatient haemodialysis service to a new, refurbished and 
fit-for-purpose location, with a dedicated isolation facility and increased capacity.  
The new facility will provide ultrapure water to facilitate HiVOLHDF as the treatment 
modality of choice. 
Objectives 
1. By June 3rd 2015, complete and submit a business case to the National 
Renal Office and the Ireland East Hospitals group (IEHG) for approval of funding.  
2. By August 21st 2015, have the contractors’ schematics for the new unit 
agreed by all stakeholders. 
3. From 5th October 2015, commence installation of water purification plant, 
centralised concentrate delivery system (CCDS) and associated ring mains. 
4. By 7th December 2015, commence quality testing and commissioning of 
water purification plant and CCDS. This intensive sampling phase will be completed 
by January 4th 2016 and will incorporate the development of a KPI. 
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5. On 8th February 2016, transfer acute haemodialysis services to the new unit 
and cease services at the current unit. 
6. By February 2016, establish a dedicated isolation unit and increase treatment 
capacity by 12.5%  
7. By February 2016, address fire officer and JCI non compliances 
8. By April 2016, perform and evaluate patient survey to ascertain their 
experience of the new facilities. 
For the purpose of this evaluation, the objectives will be divided into two distinct 
groupings; quantitative 1-4 and qualitative 5-8.  
4.5 Evaluation and this organisational development 
 
There were two significant aspects to the evaluation of this organisational 
development project. The primary evaluation was of the ultrapure water quality which 
facilitates the HiVOLHDF treatment modality. This was a quantitative evaluation, 
involving the development of a KPI, a performance measurement instrument that 
acts as an early warning indicator that foresees any deviation in the water quality, 
both chemically and microbiologically.  It also facilitates early preventative 
intervention, to ensure HiVOLHDF can remain the haemodialysis treatment of 
choice.  The secondary evaluation, which was more qualitative in nature, 
incorporated a patient satisfaction survey to ascertain the patient experience in the 
new refurbished unit when compared with the existing, old unit. 
While being cognisant of all the aforementioned frameworks and their potential 
benefit to this evaluation, the author feels the CIPP framework (Figure 5) offers the 
best and most appropriate methodology.  It is the author’s belief that it offers the 
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most logical route to evaluate this organisational development through all of its 
strands; initiation, planning, implementation and mainstreaming.  In relation to a 
project of this scale, systematic evaluation was required for all stages of each 
component to ensure the overall agreed vision was realised, and that none of the 
individual components had a debilitating influence on the overall outcome.    
 Figure 5 
 
Context Evaluation 
Within the ‘context evaluation’, the ‘what needs to be done’ phase of the CIPP model 
requires the change agent to focus on the vision, goals, the planning of its 
implementation and its evaluation.  During this phase it is critical to concentrate on 
making the change a best fit for the organisation while identifying all the resources, 
political and cultural issues.  In conjunction with this, it is imperative for the change 
agent to ensure that all key stakeholders are identified and engaged with.  In 
essence, this stage provides the opportunity for the change agent to take soundings, 
verify if the change is achievable within the current structure and identify what 
additional resources may be required. (Mertens & Wilson, 2012).  In effect this phase 
correlates directly with the initiation stage of the HSE change model.  According to 
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Stufflebeam, for context evaluation to be effective it must ‘delineate, obtain and 
provide’ the correct information in a timely efficient manner to fine tune the planning 
process. (Stufflebeam, 2001).  
Input Evaluation 
The ‘input evaluation’ phase is where fine tuning is addressed. In this phase the 
change agent and stakeholders determine the use of resources, develop strategies 
to achieve the objectives and focus/define the implementation strategy.  This phase 
concurs with the planning stage of the HSE change model. 
Process Evaluation 
During ‘process evaluation’ we have the opportunity to access how well we are 
progressing in accordance with the predetermined plan.  The purpose of this phase 
is to give the change agent the opportunity to make changes to the implementation, 
based on the circumstances and realities of implementation and couldn’t have been 
foreseen in the preparatory design stages.  It requires close monitoring of the 
project, possibly on a daily basis, which will guide and assist any alterations required 
to the project delivery.   
Product Evaluation 
‘Product evaluation’ offers the opportunity to evaluate the outcomes when compared 
with the objectives of the organisational change.  This requires having clearly defined 
criterion or standards to be achieved.  This evaluation should continue throughout 
the complete implementation, particularly at key milestones, and finally an overall 
evaluation on completion.   The essence of product evaluation is to determine 
whether the specific outcomes of the project were achieved. 
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4.6 Results: Ultrapure water quality 
 
“Those medical directors who learn, know, and embrace the requirements for 
providing high-quality dialysis water will be most successful.”                        
(Kasparek & Rodriguez, 2015) 
 
Water quality is fundamental to haemodialysis regardless of the modality; this has 
two distinct strands namely chemical quality and microbiological quality.  However 
the criticality of the quality is far more stringent with the HiVOLHDF modality of 
treatment.  A typical adult will be exposed to approximately fourteen litres of water a 
week. This is ingested orally, absorbed via the gastrointestinal tract, any excess is 
removed by the nephron in the kidney and exits the body with other waste products 
of metabolism in the urine.  By contrast, the standard thrice weekly haemodialysis 
patient is exposed to 576 litres per week via the semipermeable dialyser. In addition, 
the high volume online HDF patient is exposed typically to an additional 60 litres per 
week which is infused directly into the patient’s blood stream.  Furthermore, as the 
majority of ESRD patients have zero, or very minimal residual renal function, toxins 
in the blood remain and cannot be ‘renally’ excreted between dialysis sessions. 
 
Evidently, the requirement for stringent water quality standards for patients requiring 
dialysis is imperative versus those merely reliant on drinking water, both chemically 
and microbiologically for the aforementioned reasons. Many of the constituents 
naturally found in potable water e.g. calcium, aluminium, zinc, etc., and those added 
to make water suitable for human consumption e.g. fluoride, chlorine, chloramine, 
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etc. are at toxic levels for the dialysis patient.  These are cumulatively known as the 
chemical constituents and, as with drinking water, must achieve a different set of 
stringent quality standards. (Appendix 5). 
In addition to the chemical quality standards are the microbiological quality 
standards, which comprise two distinct markers namely the total viable count (TVC) 
and the endotoxin level (EU), the latter measured traditionally  by the limulus 
amebocyte lysate (LAL) test or increasingly  Reasoner's 2A (R2A) but less frequently 
the Tryptic soy agar (TSA) (Appendix 6). As seen from this, the standards relating to 
water quality for ultrapure water are sufficiently stringent but, as a result of significant 
technological advances readily achievable, for all modern dialysis facilities. The 
introduction of ultrapure can help in preventing dialysis treatment related 
complications. (Pontoriero, Pozzoni, Andrulli, & Locatelli, 2003) & (Coulliette & 
Arduino, 2013).   Whilst this is a requirement for all haemodialysis treatments, the 
use of ultrapure water is of utmost importance for patients undergoing HiVOLHDF. 
(Kasparek & Rodriguez, 2015), (Bernard Canaud & Lertdumrongluk, 2012), (Ward et 
al., 2000) & (Ward and Tattersall, 2015). Appendix 7 tabulates the differences 
between the United States and European pharmacopoeias (USP and EP 
respectively) in relation to water quality standards under the purified water (PW) and 
water for injection (WFI) classifications.  In 2002, with the publication of the fourth 
edition of the EP, highly purified water (HPW) was introduced.  HPW is applied in the 
production of medicinal products which sets high standards to be met in the field of 
microbiology, but where WFI is not mandatory.  
The business case was submitted and gained approval in May 2015.  Following this, 
there was the initial engagement with the water treatment plant supplier regarding 
the water quality and system specification.  This was a lengthy process involving 
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numerous meetings and clarifications relating to the engineering design and 
installation logistics.  Appendices 8 & 9 schematically represent the agreed facility 
layout and plant components. 
The specified water purification system for this project comprises the key 
components below, with the requirement to produce product water quality in 
compliance with the standards outlined in appendix 5 and appendix 6.  In addition, 
the system design took countenance of the fact that this organisation has two 
differing raw water supplies and many seasonal variations in water supply quality, 
particularly relating to nitrate levels and chlorination. (Fluck et al., 1999) & (Casey, 
Kearney, & Kerr, 2012). 
 Depth filtration 
 Organic scavenging 
 Duplexed water softening 
 Carbon adsorption with an EBCT (Empty Bed Contact Time) of > 10 mins 
 Dual pass reverse osmosis 
 Ultrafiltration 
 UV irradiance 
 Heat sanitisation module 
In conjunction with the infrastructural component of this project, as described in 
chapter three, the plant installation commenced as agreed, in October 2015.  This 
phase was completed ahead of schedule and was concluded on November 27th 
2015, thereby enabling the early commencement of the commissioning, validation 
and quality testing.  
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Validation commenced in December 2015 and was completed at the end of the 
second week in January 2016. This consisted of monthly sampling and chemical 
analysis of the incoming raw water and the product water (V 20).  Additional mid 
process samples were taken post softening, post-carbon adsorption and mid-reverse 
osmosis (V19).  The purpose of this additional sampling was to facilitate evaluation 
of the individual component stages of the complete purification process and to 
confirm its correct performance.  These results are tabulated in appendix 10 and 
confirm that this water purification design consistently provides water that surpasses 
the chemical standards for ultrapure water.  The microbiological quality validation 
followed a similar regime with samples for total viable count (TVC) and Endotoxin 
units (EU) being analysed on a weekly basis and again, consistently complied with 
the standard TVC < 0.1cfu per ml and < 0.03 EU per ml. (Appendix 11).  
 
Additionally, daily chlorine and water hardness testing is performed whilst dialysis 
machine product dialysis fluid is sampled monthly for TVC and EU (appendix 13).  
This latter test confirms that the individual flow paths through each dialysis machine 
are not contaminated and validates the complete process as producing sterile 
pyrogen-free dialysis and HiVOLHDF substitution fluid. (Ward and Tattersall, 2015).  
This provides a major step forward in reducing dialysis related complications by 
improving the biocompatibility of the total process. (Bernard Canaud & 
Lertdumrongluk, 2012).   
 
Previously at this dialysis facility standard low flux dialysis was the predominant 
modality, with only limited high flux and zero HiVOLHDF performed.  Water 
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purification consisted of a centralised water softening system and a carbon 
adsorption stage. The softened and dechlorinated water was then delivered to each 
dialysis machine, where a built in reverse osmosis unit provided further purification. 
Whilst this met the standards of the day relating to water quality for standard dialysis, 
it was unable to achieve the current more stringent microbiological standards 
required for HiVOLHDF. Appendix 14 outlines the typical water quality results 
achieved under this regime while figure 7 indicates the thresholds for dialysis water, 
standard dialysis fluid and ultrapure dialysis fluid.  When comparing chemical quality, 
this was consistently achieved.  However, in relation to the microbiological quality, 
the TVC/ml were typically > x 100 and EU/ml > x 10 than that achieved by the new 
plant.  It must be reiterated that while this would be totally unacceptable for 
HiVOLHDF it was in compliance with the requirements for standard HD. 
Figures 6 & 7 compare the microbiological count for standard dialysis results 
achieved over a typical six month period versus the new ultrapure plant over the past 
six months.  As can be seen the ultrapure system has consistently returned results of 
TVC < 0.1cfu per ml. In relation to microbiological quality there is no degree of 
tolerance from the standard TVC < 0.1cfu per ml and < 0.03 EU per ml. In the event 
of a failed result all treatments are reverted to standard or high flux and a daily 
sampling frequency is introduced.  Nightly, as opposed to the routine weekly heat 
sanitisations, are performed until two consecutive sets of samples are returned 
negative.  It is only at this stage that HiVOLHDF is reintroduced. 
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  Figure 6 
 
 Figure 7 
Meanwhile, figure 8 portrays that, from a chemical quality perspective charting nitrate 
and fluoride as markers over a six month interval, the ultrapure plant routinely 
produces water which is compliant with standards. 
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   Figure 8 
 
4.6.1 KPI Water quality 
 
A KPI is a quantitative, measurable value, whereby an organisation can rate a 
component against a defined standard over a period of time. It can facilitate an early 
warning mechanism where slight deviations from the desired outcome can trigger 
corrective action.  In selecting KPI’s it is important to choose ones that are relevant 
to the particular subject matter.  In relation to this organisational development project 
and the production of ultrapure water, the critical factor is to consistently achieve and 
maintain the required level of quality.  Historically there has been a slightly laissez-
faire approach to quality of dialysis fluids.  However, with the increasing body of 
evidence indicating a possible relationship between long-term morbidity of patients 
and dialysis fluid contamination, the consensus now is to reduce contamination to 
the absolute minimum. (Pontoriero et al., 2003).  Reassurance for the clinical team in 
relation to this was given by the creation of a KPI on chemical components of the 
water.  Four key chemical components of water were selected, aluminium, calcium, 
0
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fluoride and nitrate as the markers for use in this KPI. They were selected based on 
their proven toxic effects on the dialysis patient; dialysis dementia, muscle 
weakness, bone disease and haemolysis respectively and due to the significant 
degree of variation in levels found in source raw water.  
Parameter Normal 
Warning 
(Action) Standard 
Aluminium 
ug/L <1 2.5 10 
Calcium ug/L <400 500 2000 
Fluoride mg/L <0.02 0.05 0.2 
Nitrate mg/L <0.75 1 2 
       Figure 9 
Figure 9 highlights the normal, warning/action and the standard levels for each of the 
four components.  The warning/action levels are designed to give an early indication 
that some component of the water purification process may be deteriorating and 
requires technical intervention.  In the case of aluminium and fluoride, this would 
indicate that the reverse osmosis stages require attention as this process removes 
both.  As calcium and nitrates are removed by an ion exchange process, an 
elevation in their levels would indicate a problem relating to the water softening 
stage.  
In figure 10, we see the sampling frequency schedule agreed and adapted by this 
organisation.  This schedule is based on the UK RA/ART (Renal 
Association/Association of Renal Technologists) clinical practice guideline  (Hoenich 
et al., 2011).   
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Contaminant Recommended 
frequency 
Actual frequency 
Chlorine at least weekly online 24/7 
Hardness daily online 24/7 
TVC at least monthly monthly 
EU at least monthly monthly 
Chemical except 
chlorine 
at least every 
three months 
three monthly 
        Figure 10 
While this guideline is considered best practice Hoenich et al. state that deviations 
are acceptable but they need to be evidence based, documented and reflect local 
trends.  
4.6.2 Patient Satisfaction Survey Evaluation 
At the time of writing, there is a dearth of published information on the benefits, 
either perceived or scientifically proven, on the merits of HiVOLHDF from the 
patient’s perspective.  However, there is plenty of anecdotal evidence where patients 
describe better quality of life, higher energy levels and less intradialytic symptoms.  It 
is the author’s belief that many of the inefficiencies of standard conventional 
haemodialysis are not instantaneously observed, but are rather more cumulative in 
nature e.g. amyloid deposition and the delayed onset of carpel tunnel syndrome, and 
can take eight to ten years to clinically present.  The corollary may also be that the 
true benefits of HiVOLHDF may be masked and will require a lot of time to manifest. 
(Merkus et al., 1999).  In the continuing absence of definitive scientific evidence, it is 
interesting that in a survey of 6595 nephrology professions (57% physician and 28% 
nursing) on the subject of the best form of ‘extracorporeal dialysis’ HiVOLHDF was 
rated best amongst the European responses, and high-flux for the Asian and 
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American respondents.  Significantly, only 7% had a preference for low-flux. (Ledebo 
& Ronco, 2008). 
An anonymised patient satisfaction survey, based on the Irish Society for Quality & 
Safety in Healthcare (ISQSH) 2010 Hospital Inpatient Survey, was created by the 
author in April 2016 and issued to all patients.  The primary purpose of this survey 
was to ascertain whether the patient experience was significantly different in the new 
dialysis unit versus the old.  The selection criteria for inclusion were based on the 
fact that each patient must have been dialysed in the old unit for a minimum of two 
months, prior to their transfer to the new unit.  This was important to ensure they had 
a significant experience of the old unit.  Also, as the survey was performed in April, 
the patient’s experience of the new unit was based on use of the new facility for two 
months. The questionnaires were issued on a Wednesday and a Thursday which 
represented the second weekly treatment for all patients on a thrice weekly 
treatment plan.  A sample of the questionnaire is included as appendix 15. and uses 
a one to five point scale often referred to as Likert scaling. 
In total, 40 patient satisfaction surveys were completed from a total possible 
maximum of 44.  For the purpose of this evaluation, the following questions were 
identified as the best criterion to gain an insight into the patient’s perspective, in 
relation to the environment and the overall impression. 
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The dialysis environment: 
 
   Chart 1    Chart 2 
In relation to the new unit been too quiet (chart 1) almost three quarters 73% of 
respondents either disagreed or strongly disagreed and when asked in relation to 
how sociable it is (chart 2) 56%  disagreed or strongly disagreed that it was less 
sociable when compared with to old unit.  What is interesting is the close correlation 
with those who agreed with the statements, 18% and 20% respectively.  There are 
two potential reasons for this; the new unit offers larger treatment areas and greater 
separation between patients and the background noise is dramatically reduced in the 
new unit.   
 
 
 
 
 
 
 
The new unit is too 
quiet? 
Strongly
agree
Agree
Disagree
Strongly
disagree
Not relevant
The new unit is less 
sociable? 
Strongly
agree
Agree
Disagree
Strongly
disagree
Not relevant
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Overall impression 
 
   Chart 3    Chart 4 
Charts three and four outline the patients direct responses  to a comparison of both 
units from an overall impression perspective.  A highly significant 95% thought the 
new unit was excellent or good while just over half 53% had the same impressions of 
the old unit. 
Patient wellbeing 
 
           Chart 5 
New Unit 
Excellent
Good
Fair
Poor
Old Unit 
Excellent
Good
Fair
Poor
Overall I feel better on 
my non dialysis days 
now, when compared 
with when I was 
dialysed in the old 
unit? 
Strongly agree
Agree
Disagree
Strongly
disagree
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What the author finds significant with the results in chart 5 are that while they are not 
scientific and are anecdotal they do, albeit in a very small sample size, concur with 
the hypotheses of HiVOLHDF being perceived as offering better patient outcomes. 
4.7 Dialysis and the environment  
 
During the water purification process, water consumption is very high when creating 
ultrapure fluid.  With technological advances, the current process of reverse osmosis 
has a rejection rate (concentrate) of approximately 35%.  This equates to the 
requirement for 135 litres to create 100 litres of ultrapure water, which is 
approximately 300 litres per week is concentrate (reject water) in the treatment of a 
single patient.   With previous technologies, this has been as high as 60% or 
approximately 500 litres for a single patient treatment.  The significant efficiencies 
achieved   have in part resulted from membrane design but also from the double 
pass concept.  
 Figure 11 
 With double pass reverse osmosis the reject water from the second reverse 
osmosis unit is fed back to the input of the first (Figure 11).  The reject water from 
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the process of reverse osmosis is classified as ‘greywater.’  For green-field dialysis 
unit developments, greater efficiencies can be achieved by rerouting and using this 
reject water for irrigation systems and flushing of toilets etc. 
4.8 Conclusion 
 
On reflection, the author found that the adaption of the evaluation frameworks to the 
various components of this operational development was not an exact science.  As 
most of the frameworks are very educational and training focused, their relevance 
and applicability to engineering type projects are more tenuous.  However, the 
author did find that the ‘Logic’ and components of DECIDE and CIPP approaches 
were easier to apply and appeared more relevant to this organisational development.  
This highlights the benefit of the mixed method approach when considering both 
quantitative and qualitative data.  
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5 Conclusion 
5.1 Introduction  
Through the journey of this thesis, the author has introduced the technical 
complexities pertinent to the treatment of renal patients by dialysis. This 
organisational development involved applying an engineering solution to address 
one of the key requirements to facilitate HiVOLHDF; high quality injectable grade 
water i.e. ultrapure water.  In addition, this involved relocation of the existing 
inpatient acute dialysis unit to a fit for purpose, and technically state-of-the-art 
facility. This also addressed issues of non-compliance with recommended best 
practice in a number of areas, notably the introduction of a dedicated isolation zone 
for patients requiring isolation. 
5.2 Project Impact 
From the literature review, it has been unequivocally demonstrated that water quality 
is an essential component to the dialysis process. However, as of 2016, there is not 
a scientific consensus with regard to whether HiVOLHDF is a superior treatment of 
ESRD patients with regard to mortality and morbidity.  Whilst this may be the current 
case, it is the author’s belief that this will be forthcoming in due course.  In the 
interim, it should be considered best practice to strive towards implementation of 
ultrapure water systems in all dialysis units and in particular, whilst performing 
HiVOLHDF, while we await the evidence.  This viewpoint is compounded by the fact 
that there have been no negative reports from the studies reviewed, relating to 
patient outcomes with HiVOLHDF versus alternative conventional haemodialysis 
treatments. In addition, it would definitely seem prudent that when designing new 
dialysis facilities, ultrapure water should be the standard specification. 
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5.2.1 Culture 
The author has, and benefits from, working in an organisation where a culture of 
continually striving for excellence in both patient care and patient outcomes 
predominately prevails.  The culture was evident during this organisational 
development project from its initial conceptual stage in 2011 with all internal 
stakeholders, through to its implementation in 2016.  Working in this environment 
adds synergy to projects of this nature, and in such a large organisation there is a 
continual evolving process of change and a corporate buy-in exists, adding 
momentum and traction to the change management. (Weick & Quinn, 1999).   
5.2.2Theory 
"Change is the law of life and those who look only to the past or present are certain 
to miss the future." (John. F. Kennedy). 
In relation to organisational change we have discovered that various theories and 
models exist.  From the initial, quite restrictive linear three step model by Lewin to 
the extended Kotter’s eight step model, which again, as discovered, proved quite 
restrictive, limited and lacking in comparison to the more applicable and relevant 
Senior & Swailes and HSE models.  These latter two models incorporate feedback 
and an interconnected system of interconnectivity between the phases.  This 
enables a fine tuning and continuous monitoring of all phases but in addition 
facilitates the change agent to modify phases mid process.  While the author is of the 
belief that there is not a one size fits all model in relation to organisational change, 
the HSE model was the best fit for this particular organisational development.  It’s 
clearly defined phases of IPIM (Initiation, Planning, Implementation & 
Mainstreaming) offered a clearly logical process to implement and monitor this 
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project from inception to delivery.  We also explored the significance of resistance, 
power, influence, culture and the importance of leadership from the change agent.  
Following this, we explored the process of evaluation and its significance in relation 
to organisational development. As discussed, numerous evaluation frameworks exist 
and again similar to the change models there is not a one size fits all.  Best practice 
would appear to be a marriage of the best components of many, which can be 
adapted to the specific organisational change project.  In relation to the quantitative 
analysis, for this operational development, it has been proven that ultrapure water is 
consistently and reliably reproducible using standard water purification technologies.  
Regarding the qualitative analysis, in the patient and staff satisfaction surveys it was 
fascinating to find that the softer ‘feel good’ factors as reported by the patients in the 
new unit dominated results.  
5.3 Strengths 
This organisational development project has given the author the opportunity to 
experience the numerous and intricate aspects of managing change and its many 
components.  A significant achievement was achieving ultrapure water and thereby 
HiVOLHDF, and a dedicated patient isolation area within this new state of the art 
facility.  It has also highlighted the importance of collaboration, communication and 
compromise by all stakeholders to achieve a vision under the guidance of the 
change agent.  
5.4 Limitations 
As highlighted in the first SWOT analysis, the most pressing limitation of this 
organisational development project is the increased capacity.  From the statistics 
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quoted in chapter 1, the requirement for dialysis is increasing globally, therefore 
within five years it is conceivable that this organisation will require greater treatment 
capacity. 
5.5 Recommendations 
The possibility of the combination of certain aspects of current treatment modalities 
appears to be very much a live reality in the near future.  In this way, there is a 
realistic hope that more beneficial patient outcomes particularly in relation to 
treatment quality, mortality and morbidity, can be provided.  The endless possibilities 
of change coupled with the continuous development of new technologies bode well 
for all future medical treatments particularly in relation to patients requiring treatment 
of ESRD. To realise the future and to make all technological innovations a reality for 
all patients in need of renal replacement therapies, technical acumen and leadership 
is required to ensure the change is proven, assimilated and becomes the new way 
‘we do things’.  
5.6 Conclusion 
Finally, some years ago in 1991 as a recently qualified clinical engineer MSc at one 
of London’s largest teaching hospitals, I often recall a conversation with a PhD 
qualified clinical engineering colleague who entered the still emerging profession 15 
years previously.  He relayed a conversation he had in 1986 with an eminent 
consultant nephrologist. The consultant questioned the relevance of such a highly 
skilled and qualified clinical engineer applying himself to the speciality of 
haemodialysis, as 'all the technical developments associated with the treatment of 
patients with kidney failure had been accomplished'. I regularly recall this 
conversation been relayed by my colleague and mentor, with a wry smile.  Today, I 
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also reflect that some thirty years later and with many ground breaking innovative 
technological advances, we still appear to be a significant distance away from a 
consensus on some of the highly technical, but fundamental functions of the nephron 
and more specifically the glomerulus in relation to molecular clearance in the 
treatment of ESRD patients by any modality of haemodialysis. In the past 25 years 
alone, examples of technological advancements include moving from acetate-based 
dialysis to the more biocompatible bicarbonate, closed loop ultrafiltration for fluid 
removal, the revolution in water purification technologies, urea kinetic modelling, 
relative and actual blood volume monitoring, real time fistula recirculation monitoring, 
heparin free dialysis and on-line molecular clearance.  There is currently no reason 
to believe that HiVOLHDF won’t be the next breakthrough.  
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Appendices 
Appendix 1 Stakeholder analysis (1) 
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Appendix 2 Stakeholder analysis (2) 
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Appendix 3 SWOT (1) 
 
Appendix 4 SWOT (2) 
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Appendix 5 Chemical constituents of drinking water versus dialysis water 
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Chemical limits allowable in municipal drinking water and dialysis water (5,11,23) 
Parameter 
Municipal 
drinking water 
Health effect 
Dialysis 
water 
Health effect 
Toxic chemicals 
(mg/l) 
    
 Aluminum
1
 0.05–0.2 Anemia, osteomalacia 0.01 “Dialysis dementia” 
 Chloramine
2
 4.0 Eyes, nose; GI discomfort, 
anemia 
0.1 
3
 Acute hemolytic 
anemia 
 Chlorine
2
 4.0 Eyes, nose; GI discomfort, 
anemia 
0.5 
3
  
 Total chlorine –  0.1  
 Copper
4
 1.3 GI distress, liver/kidney 0.1  
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Parameter 
Municipal 
drinking water 
Health effect 
Dialysis 
water 
Health effect 
damage 
 Fluoride 4.0 Bone disease 0.2 Toxicity, bone disease 
 Lead
4
 0.015 Neurological damage, fatal 
hemolysis 
0.005 GI pain, muscle 
weakness 
 Nitrate (as N) 10 Blue-baby syndrome, 
shortness breath 
2.0 Methemoglobinemia 
 Sulfate –  100 Nausea, metabolic 
acidosis 
 Zinc – Nausea, vomiting, fever, 
anemia 
0.1  
Trace elements 
(mg/l) 
    
 Antimony 0.006  0.006  
 Arsenic 0.010  0.005  
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Parameter 
Municipal 
drinking water 
Health effect 
Dialysis 
water 
Health effect 
 Barium 2  0.1  
 Beryllium 0.004  0.0004  
 Cadmium 0.005  0.001  
 Chromium 0.10  0.014  
 Mercury 0.002  0.0002  
 Selenium 0.05  0.09  
 Silver
1
 0.10  0.005  
 Thallium 0.002  0.002  
 
1This limit is part of the National Secondary Drinking Water Regulation, which is nonenforceable. 
2This is the highest allowable limit in drinking water, defined as the Maximum Residual Disinfectant 
Level. 
3Chloramine and Free Chlorine limits are only listed in the CMS standards, not in the ANSI/AAMI/ISO 
recommendations. 
4This limit is the action level if more than 10% of samples exceed this threshold. 
101 
 
Appendix 6 Microbial constituents of drinking water versus dialysis water 
 
PMC full text: Semin Dial. Author manuscript; available in PMC 2015 Oct 7. 
 
 
Microbial standards for municipal drinking water, dialysis water, and dialysate 
(standard and ultrapure) (2,5–8,11,23). The heterotrophic bacteria (HPC) and Total 
Viable Count are comparable when using Reasoners 2A (R2A) for 7 days at 17–23°C 
Parameter 
Municipal drinking 
water 
Conventional  
dialysis water 
Conventional  
dialysate/  
Dialysis fluid 
Ultrapure 
dialysate 
Heterotrophic bacteria 
(HPC) 
≤500 CFU/ml – – – 
Total Viable Count     
 CMS max allowable 
limit
1
 
– <200 CFU/ml <200 CFU/ml <0.1 CFU/ml 
 CMS action level
1
,
2
  50 CFU/ml 50 CFU/ml – 
 ANS max allowable 
limit
3
 
– <100 CFU/ml <100 CFU/ml <0.1 CFU/ml 
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Parameter 
Municipal drinking 
water 
Conventional  
dialysis water 
Conventional  
dialysate/  
Dialysis fluid 
Ultrapure 
dialysate 
 ANS action level
2
,
3
  50 CFU/ml 50 CFU/ml – 
Endotoxin     
 CMS max allowable 
limit
1
 
– <2 EU/ml <2 EU/ml <0.03 EU/ml 
 CMS action level
1
,
2
  1 EU/ml 1 EU/ml – 
 ANS max allowable 
limit
3
 
– <0.25 EU/ml <0.5 EU/ml <0.03 EU/ml 
 ANS action level
2
,
3
  0.125 EU/ml 0.25 EU/ml – 
1The Centers for Medicare and Medicaid Services (CMS), Department of Health and 
Human Services set the regulations for maximum allowable limits and action levels for 
dialysis facilities to be certified under the Medicare program (5); these are currently based 
upon the 2004 recommendations from the Association for the Advancement of Medical 
Instrumentation (AAMI) (6). 
2The action level is the concentration at which corrective measures are to be immediately 
conducted to reduce the bacteria and/or endotoxin levels, which are typically 50% of the 
maximum allowable level. 
3The American National Standard (ANS) published through American National Standards 
Institute (ANSI)/AAMI/International Organization for Standardization (ISO) are 
voluntary, recommended practices for dialysis water (8,11) and dialysis fluid (7,8). 
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Appendix 7 United States Pharmacopeia and European Pharmacopeia 
standards 
 
  
 
-  EP (European Pharmacopoeia); (2002) 
-  USP (United States Pharmacopeia). 
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Appendix 8 New facility schematic 
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Appendix 9 New plant room schematic 
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Appendix 10 Sample chemical results 
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Appendix 11  Ultrapure water standards 
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Appendix 12 Sample microbial results 
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Appendix 13  Dialysis fluid samples 
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Appendix 14  TVC/LAL results for the previous unit 
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Appendix 15   Patient satisfaction survey 
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Appendix 16 Poster abstract 
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